Efficacy of an orlistat‐resveratrol combination for weight loss in subjects with obesity: A randomized controlled trial

• Published in: Obesity (Silver Spring, Md.) Vol. 24; no. 7; pp. 1454 - 1463
• Main Authors: Arzola‐Paniagua, María Angélica, García‐Salgado López, Enrique Raúl, Calvo‐Vargas, Cesar G., Guevara‐Cruz, Martha
• Format: Journal Article
• Language: English
• Published: United States Blackwell Publishing Ltd 01.07.2016
• Subjects: Adult; Aged; Anthropometry; Anti-Obesity Agents - therapeutic use; Body Mass Index; Caloric Restriction; Clinical trials; Compliance; Cytokines; Diet; Double-Blind Method; Drug Therapy, Combination; Energy Intake - drug effects; FDA approval; Female; Glucose; Humans; Lactones - administration & dosage; Lactones - therapeutic use; Leptin - blood; Lipids; Male; Metabolism; Mexico; Middle Aged; Musculoskeletal system; Nutrition research; Obesity; Obesity - blood; Obesity - drug therapy; Placebos; Rodents; Stilbenes - administration & dosage; Stilbenes - therapeutic use; Studies; Treatment Outcome; Triglycerides - blood; Weight control; Weight Loss
• ISSN: 1930-7381; 1930-739X; 1930-739X
• DOI: 10.1002/oby.21523

Objective To evaluate the efficacy of an orlistat‐resveratrol (O‐R) combination in subjects with obesity over a 6‐month period. Methods This study was a double‐blind, parallel, randomized controlled clinical trial. Patients fulfilling the selection criteria (age from 20 to 60 years and body mass index (BMI) ≥30 and ≤39.9 kg/m2) consumed an energy‐reduced diet with 500 fewer calories than their usual diet for 2 weeks. Then the participants were randomly assigned to four groups, placebo, resveratrol, orlistat, or O‐R, and they consumed the energy‐reduced diet for 6 months. The study consisted of seven visits. During each visit, a 24‐h recall was performed, along with measurements of anthropometric and serum biochemical parameters. Results A total of 161 participants were selected. Of these, 84 participants completed the study. A significant weight loss of −6.82 kg (95% CI −8.37 to −5.26) was observed in the O‐R group compared with −3.50 kg (−5.05 to −1.95, P = 0.021) in the placebo group. In contrast, the −6.02 kg (−7.68 to −4.36) orlistat and −4.68 kg (−6.64 to −2.71) resveratrol monotherapy losses did not significantly differ from the placebo. Significant decreases in BMI, waist circumference, fat mass, triglycerides, leptin, and leptin/adiponectin ratio were observed with the O‐R combination. Conclusions The O‐R combination was the most effective weight loss treatment.